Considerations when prescribing opioid agonist therapies for people living with HIV
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2375448 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Adati Tarfa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Yale AIDS Program, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, HIV Infections, Buprenorphine, Opiate Substitution Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institutes on Drug Abuse.
Abstract (Originalsprache)
INTRODUCTION: Medications for opioid use disorder (MOUD) include opioid agonist therapies (OAT) (buprenorphine and methadone), and opioid antagonists (extended-release naltrexone). All forms of MOUD improve opioid use disorder (OUD) and HIV outcomes. However, the integration of services for HIV and OUD remains inadequate. Persistent barriers to accessing MOUD underscore the immediate necessity of addressing pharmacoequity in the treatment of OUD in persons with HIV (PWH). AREAS COVERED: In this review article, we specifically focus on OAT among PWH, as it is the most commonly utilized form of MOUD. Specifically, we delineate the intersection of HIV and OUD services, emphasizing their integration into the United States Ending the HIV Epidemic (EHE) plan by offering comprehensive screening, testing, and treatment for both HIV and OUD. We identify potential drug interactions of OAT with antiretroviral therapy (ART), address disparities in OAT access, and present the practical benefits of long-acting formulations of buprenorphine, ART, and pre-exposure prophylaxis for improving HIV prevention and treatment and OUD management. EXPERT OPINION: Optimizing OUD outcomes in PWH necessitates careful attention to diagnosing OUD, initiating OUD treatment, and ensuring medication retention. Innovative approaches to healthcare delivery, such as mobile pharmacies, can integrate both OUD and HIV and reach underserved populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale AIDS Program, Yale University School of Medicine, New Haven, CT, USA.
- Internal Medicine, Renaissance School of Medicine at Stony Brook University, Northport, NY, USA.
- Veterans Administration Connecticut Healthcare System, West Haven, CT, USA.
Förderung
- NIDA NIH HHS
- National Institutes on Drug Abuse
Zitieren
APA
Tarfa, A., Lier, A. J., Shenoi, S. V., & Springer, S. A. (2024). Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2375448
Vancouver
Tarfa A, Lier AJ, Shenoi SV, Springer SA. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2375448
BibTeX
@article{Tarfa2024,
author = {Tarfa, Adati and Lier, Audun J and Shenoi, Sheela V and Springer, Sandra A},
title = {Considerations when prescribing opioid agonist therapies for people living with HIV},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2375448}
}
EUVIMED